Overview

Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids

Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Will oral supplementation with Omega 3 free fatty acids in obese Barrett's esophagus subjects downregulate pro-neoplastic and pro-inflammatory pathways in the esophagus to anti-inflammatory pathway?
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic